文献速递乳房整形与再造创面修复

静脉氨甲环酸在假体乳房再造中安全减少血肿且不增加血栓栓塞事件

Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events.
PubMed 文献 · Plast Reconstr Surg · 2020-01-01

单中心回顾性队列纳入2015至2016年连续868例即刻两阶段假体乳房再造(499例女性),其中116例(217侧)接受静脉氨甲环酸、383例(651侧)未接受。控制年龄、高血压和再造类型后,氨甲环酸组血肿发生率低于未用组(0.46%对2.9%,p=0.018),未观察到血栓栓塞等不良事件。

要点

  • 静脉氨甲环酸可降低假体乳房再造术后血肿风险
  • 本队列未观察到血栓栓塞等氨甲环酸不良事件
  • 年龄和高血压独立增加血肿风险

核心结论

  • 静脉氨甲环酸可安全降低假体乳房再造的血肿风险,但仍需前瞻性随机研究进一步证实。

研究设计与样本

  • 单中心回顾性队列研究,分析2015至2016年连续868例即刻两阶段假体乳房再造(499例女性)。
  • 干预组116例(217侧)在乳房切除切口前接受静脉氨甲环酸1000 mg、术毕再给1000 mg,对照组383例(651侧)未使用。
  • 采用Fisher精确检验和Mann-Whitney-Wilcoxon检验,并以多因素logistic回归校正混杂因素。
  • 证据等级为治疗性III级。

主要发现

  • 控制年龄、高血压和再造类型(胸肌前与胸肌下)后,氨甲环酸组血肿1例(0.46%),未用组19例(2.9%),p=0.018。
  • 未观察到静脉氨甲环酸的不良反应,包括血栓栓塞现象。
  • 多因素分析显示年龄和高血压独立增加血肿风险。
  • 两组患者特征与合并症相似。

临床怎么用

  • 对拟行即刻两阶段假体乳房再造的患者,可考虑围手术期静脉氨甲环酸以降低血肿风险。
  • 对年龄较大或合并高血压者应加强血肿风险防范。

局限性

  • 为单中心回顾性队列研究,证据等级III级,需前瞻性随机研究进一步 corroborate。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antifibrinolytic medications, such as tranexamic acid, have recently garnered increased attention. Despite its ability to mitigate intraoperative blood loss and need for blood transfusion, there remains a paucity of research in breast reconstruction. The authors investigate whether intravenous tranexamic acid safely reduces the risk of hematoma following implant-based breast reconstruction. METHODS: A single-center retrospective cohort study was performed to analyze all consecutive patients undergoing immediate two-stage implant-based breast reconstruction following mastectomy between 2015 and 2016. The incidence of postoperative hematomas and thromboembolic events among all patients was reviewed. The patients in the intervention group received 1000 mg of intravenous tranexamic acid before mastectomy incision and 1000 mg at the conclusion of the procedure. Fisher's exact test and the Mann-Whitney-Wilcoxon test were used. Multivariate logistic regression models were performed to study the impact of intravenous tranexamic acid after adjusting for possible confounders. RESULTS: A total of 868 consecutive breast reconstructions (499 women) were reviewed. Overall, 116 patients (217 breasts) received intravenous tranexamic acid, whereas 383 patients (651 breasts) did not. Patient characteristics and comorbidities were similar between the two the groups. Patients who received tranexamic acid were less likely to develop hematomas [n = 1 (0.46 percent)] than patients who did not [n = 19 (2.9 percent)] after controlling for age, hypertension, and type of reconstruction (prepectoral and subpectoral) (p = 0.018). Adverse effects of intravenous tranexamic acid, including thromboembolic phenomena were not observed. Multivariate analysis demonstrated that age and hypertension independently increase risk for hematoma. CONCLUSIONS: Intravenous tranexamic acid safely reduces risk of hematoma in implant-based breast reconstruction. Further prospective randomized studies are warranted to further corroborate these findings. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.

来源:Plast Reconstr Surg,查看原文。版权归原作者所有。

引用

  1. Weissler JM, Banuelos J, Jacobson SR, et al. Intravenous Tranexamic Acid in Implant-Based Breast Reconstruction Safely Reduces Hematoma without Thromboembolic Events. Plast Reconstr Surg. 2020. PMID: 32740567. doi:10.1097/PRS.0000000000006967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。